Literature DB >> 15953348

Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.

Lotte de Groote1, Rosana G Peñalva, Cornelia Flachskamm, Johannes M H M Reul, Astrid C E Linthorst.   

Abstract

Corticotropin-releasing factor (CRF) mediates various aspects of the stress response. To differentiate between the roles of CRF(1) and CRF(2) receptor subtypes in monoaminergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity and behaviour we compared the effects of CRF and urocortin 1 with those of the selective CRF(2) receptor ligands urocortin 2 and urocortin 3. In vivo microdialysis in the rat hippocampus was used to assess free corticosterone, extracellular levels of serotonin (5-HT) and noradrenaline (NA), and their metabolites 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), respectively. Intracerebroventricular (i.c.v.) injection of CRF and urocortin 1, 2 and 3 (1.0 microg) increased hippocampal levels of 5-HT and 5-HIAA. CRF and urocortin 1 increased NA and MHPG, whereas urocortin 2 and urocortin 3 elevated MHPG, but not NA levels. CRF and the urocortins induced an immediate increase in behavioural activity. CRF and urocortin 1 mainly caused grooming and exploratory behaviour. In contrast, urocortin 2 and urocortin 3 both induced exploratory behaviour, but not grooming, and increased time spent eating food pellets. All urocortins, but not CRF, suppressed food intake 4-6 h after injection. Hippocampal free corticosterone levels were elevated by CRF, urocortin 1 and 3, but not by urocortin 2. The time courses of the CRF- and urocortin 1-induced responses were significantly prolonged as compared to those of the CRF(2) receptor ligands. The stimulatory changes evoked by CRF and urocortin 1 were present up to 4-6 h after injection, whereas the effects of urocortin 2 and urocortin 3 returned to baseline within 2.5 h after injection. Pre-treatment with the selective antagonist antisauvagine-30 (5.0 microg, i.c.v.) confirmed that the effects of urocortin 3 were CRF(2) receptor-mediated. The differential time course of the monoaminergic, neuroendocrine and behavioural effects of CRF and urocortin 1, as compared to urocortin 2 and urocortin 3, and the specific behavioural pattern induced by the CRF(2) receptor ligands, suggest a distinct role for CRF(2) receptors in the stress response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953348     DOI: 10.1111/j.1471-4159.2005.03164.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization.

Authors:  D A Kupferschmidt; P G Klas; S Erb
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Teneurin C-terminal associated peptide-1 blocks the effects of corticotropin-releasing factor on reinstatement of cocaine seeking and on cocaine-induced behavioural sensitization.

Authors:  David A Kupferschmidt; David A Lovejoy; Susan Rotzinger; Suzanne Erb
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Delayed satiety-like actions and altered feeding microstructure by a selective type 2 corticotropin-releasing factor agonist in rats: intra-hypothalamic urocortin 3 administration reduces food intake by prolonging the post-meal interval.

Authors:  Eva M Fekete; Koki Inoue; Yu Zhao; Jean E Rivier; Wylie W Vale; Attila Szücs; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2006-10-04       Impact factor: 7.853

4.  Urocortin 2 increases c-Fos expression in serotonergic neurons projecting to the ventricular/periventricular system.

Authors:  Matthew W Hale; Christopher E Stamper; Daniel R Staub; Christopher A Lowry
Journal:  Exp Neurol       Date:  2010-04-09       Impact factor: 5.330

Review 5.  Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.

Authors:  Glenn R Valdez
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  The effect of corticotropin-releasing factor on prepulse inhibition is independent of serotonin in Brown Norway and Wistar-Kyoto rats.

Authors:  Jane E Sutherland; Michelle E Page; Lisa H Conti
Journal:  Pharmacol Biochem Behav       Date:  2008-01-16       Impact factor: 3.533

Review 7.  Urocortin and the brain.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Prog Neurobiol       Date:  2007-11-07       Impact factor: 11.685

8.  Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors.

Authors:  Bing Mo; Na Feng; Kenneth Renner; Gina Forster
Journal:  Brain Res Bull       Date:  2008-03-04       Impact factor: 4.077

9.  Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior.

Authors:  Edward G Meloni; Catherine L Reedy; Bruce M Cohen; William A Carlezon
Journal:  Biol Psychiatry       Date:  2007-12-03       Impact factor: 13.382

10.  Coordinated changes in energy intake and expenditure following hypothalamic administration of neuropeptides involved in energy balance.

Authors:  N M Semjonous; K L Smith; J R C Parkinson; D J L Gunner; Y-L Liu; K G Murphy; M A Ghatei; S R Bloom; C J Small
Journal:  Int J Obes (Lond)       Date:  2009-06-02       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.